Purple Biotech Ltd

DB:1YI Stock Report

Market Cap: €9.7m

Purple Biotech Management

Management criteria checks 3/4

Purple Biotech's CEO is Gil Efron, appointed in Jul 2022, has a tenure of 2.42 years. total yearly compensation is $1.04M, comprised of 29.6% salary and 70.4% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth €24.90K. The average tenure of the management team and the board of directors is 4.3 years and 3.7 years respectively.

Key information

Gil Efron

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage29.6%
CEO tenure2.4yrs
CEO ownership0.3%
Management average tenure4.3yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gil Efron's remuneration changed compared to Purple Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$12m

Jun 30 2024n/an/a

-US$16m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$1mUS$308k

-US$20m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$19m

Dec 31 2022US$1mUS$365k

-US$22m

Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$757kUS$357k

-US$18m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$758kUS$266k

-US$29m

Sep 30 2020n/an/a

-US$30m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$579kUS$263k

-US$5m

Compensation vs Market: Gil's total compensation ($USD1.04M) is above average for companies of similar size in the German market ($USD472.12K).

Compensation vs Earnings: Gil's compensation has been consistent with company performance over the past year.

CEO

Gil Efron (58 yo)

2.4yrs

Tenure

US$1,040,342

Compensation

Mr. Gil Efron, CPA, M.A., serves as Chief Executive Officer of Purple Biotech Ltd. since July 10, 2022. He served as Chief Financial Officer at Purple Biotech Ltd.(formerly known as Kitov Pharma Ltd) sinc...

Leadership Team

NamePositionTenureCompensationOwnership
Gil Efron
Chief Executive Officer2.4yrsUS$1.04m0.26%
€ 24.9k
Michael Schickler
Head of Clinical & Regulatory Affairs4.9yrsUS$482.37kno data
Ido Morpurgo
Vice President of Operations4.3yrsno datano data

4.3yrs

Average Tenure

58yo

Average Age

Experienced Management: 1YI's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yael Margolin
Independent Directorless than a yearno datano data
Simcha Rock
Independent Director11.4yrsUS$358.66kno data
Eric Rowinsky
Independent Chairman of the Board5.2yrsno datano data
Ido Agmon
Independent Director8.5yrsno datano data
Robert Gagnon
Independent Director3.8yrsno datano data
Eyal Gottlieb
Member of Scientific Advisory Board1.7yrsno datano data
Suzana Nahum-Zilberberg
Independent Director3.6yrsno datano data
Isaac Israel
Director12.2yrsUS$381.79kno data
Sunil Sharma
Member of Scientific Advisory Board1.7yrsno datano data
Steven Maron
Member of Scientific Advisory Board1.7yrsno datano data

3.7yrs

Average Tenure

53yo

Average Age

Experienced Board: 1YI's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/14 13:46
End of Day Share Price 2024/09/16 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Purple Biotech Ltd is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.
Raghuram SelvarajuRodman & Renshaw, LLC